Get the Stockscreener App
0.8276
0.17%
-0.0014
After Hours:
.80
-0.0276
-3.33%
Palisade Bio Inc stock is traded at $0.8276, with a volume of 36,946.
It is down -0.17% in the last 24 hours and down -36.58% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$0.829
Open:
$0.8314
24h Volume:
36,946
Relative Volume:
0.03
Market Cap:
$2.42M
Revenue:
-
Net Income/Loss:
$-14.07M
P/E Ratio:
-0.0592
EPS:
-13.99
Net Cash Flow:
$-12.56M
1W Performance:
-12.56%
1M Performance:
-36.58%
6M Performance:
-77.63%
1Y Performance:
-86.48%
1-Day Range:
$0.80
$0.8329
1-Week Range:
$0.80
$0.97
52-Week Range:
$0.80
$9.65
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
0.8276 | 2.42M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Palisade Bio Inc Stock (PALI) Latest News
Palisade Bio secures Canadian tax credit for drug study By Investing.com - Investing.com Nigeria
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) - The Manila Times
Palisade Bio secures Canadian tax credit for drug study - Investing.com India
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from - GlobeNewswire
Canadian Government Backs This Promising Ulcerative Colitis TreatmentWhat's Behind the $1.39M Investment? - StockTitan
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Autonomix Medical, Inc. Participates in the Virtual Investor 'Top 5 for '25” On-Demand Conference - The Manila Times
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand - Big News Network
Inside Palisade Bio's Ambitious 2025 Roadmap: 5 Critical Growth Drivers Revealed - StockTitan
PALI stock plunges to 52-week low, touches $1.34 - MSN
PALI-2108 colon-activated prodrug prevents ulcerative colitis progression - BioWorld Online
PALI’s Q2 earnings predictions: What the experts say - US Post News
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewswire
Q4 Earnings Roundup: Children's Place (NASDAQ:PLCE) And The Rest Of The Apparel Retailer Segment - The Globe and Mail
Palisade Bio's UC Drug Outperforms Standard Treatments in Preclinical StudiesKey Data Unveiled - StockTitan
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Reviewing Protara Therapeutics (NASDAQ:TARA) and Palisade Bio (NASDAQ:PALI) - Defense World
JPMorgan Chase & Co. Purchases Shares of 8,200 Palisade Bio, Inc. (NASDAQ:PALI) - Defense World
PALI stock touches 52-week low at $1.32 amid market challenges - Investing.com
PALI stock touches 52-week low at $1.32 amid market challenges By Investing.com - Investing.com South Africa
Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress - The Manila Times
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress - GlobeNewswire
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - The Manila Times
Palisade Bio CEO to Present at Webull Healthcare Investment Webinar This January - StockTitan
Palisade Bio reports positive data for UC drug trial - MSN
Palisade Bio begins MAD cohorts of Phase Ia/b ulcerative colitis therapy trial - Yahoo! Voices
Palisade Bio reports positive data for UC drug trial By Investing.com - Investing.com Australia
Puma Samples 601.33 g/t Gold at its McKenzie Gold Project - The Manila Times
Palisade Bio Completes All Five SAD Cohorts and Advances to - GlobeNewswire
Palisade Bio's Ulcerative Colitis Drug PALI-2108 Shows Strong Safety Profile in Phase 1 Study - StockTitan
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Palisade Bio Awards Stock Options to New Employee Under Inducement Plan - StockTitan
Palisade Bio (NASDAQ:PALI) Trading Up 2.9% – Here’s What Happened - Defense World
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board - Markets Insider
Dr. Brian Feagan Appointed to Palisade Bio Clinical Advisory Board - citybiz
Palisade Bio Strengthens Clinical Advisory Board with Leading Gastroenterology Expert for UC Drug Development - StockTitan
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan
AleAnna, Inc. Announces Completion of Business Combination between Swiftmerge Acquisition Corp. and AleAnna Energy, LLC - The Manila Times
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - GlobeNewswire
Palisade Bio Raises $5M in Public Offering to Advance Phase 1 Clinical Trial Pipeline - StockTitan
What's Going On With Palisade Bio Stock On Thursday? - Benzinga
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - The Manila Times
Palisade Bio Raises $5M in Public Offering to Advance Key Clinical Trial of PALI-2108 - StockTitan
Nasdaq Down 50 Points; US Initial Jobless Claims Rise - Benzinga
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket - Benzinga
PALI Stock Plummets to 52-Week Low at $2.13 Amid Market Struggles - Investing.com
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects - GlobeNewswire
Palisade Bio Reports Promising Safety Data in Phase 1 Ulcerative Colitis Drug Trial | PALI Stock News - StockTitan
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Palisade Bio Inc Stock (PALI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wei Binxian | Director |
Nov 21 '24 |
Option Exercise |
0.00 |
388 |
0 |
855 |
| Wei Binxian | Director |
Jun 11 '24 |
Option Exercise |
0.00 |
465 |
0 |
467 |
| Williams Donald Allen | Director |
Jun 11 '24 |
Option Exercise |
0.00 |
340 |
0 |
340 |
| Jones Mitchell Lawrence | Chief Medical Officer |
May 28 '24 |
Option Exercise |
0.00 |
4,290 |
0 |
4,313 |
| Finley John David | CEO, CFO, Director |
May 28 '24 |
Option Exercise |
0.00 |
7,068 |
0 |
14,079 |
| Williams Donald Allen | Director |
May 28 '24 |
Buy |
4.86 |
1,000 |
4,863 |
1,000 |
| Finley John David | CEO, CFO, Director |
May 24 '24 |
Buy |
4.81 |
1,000 |
4,810 |
8,437 |
| Jones Mitchell Lawrence | CEO, CFO, Director |
May 06 '24 |
Option Exercise |
0.00 |
460 |
0 |
880 |
| Finley John David | CEO, CFO, Director |
May 06 '24 |
Option Exercise |
0.00 |
443 |
0 |
6,832 |
| Finley John David | CEO, CFO, Director |
Mar 11 '24 |
Option Exercise |
0.00 |
5,558 |
0 |
96,849 |
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):